Last updated on February 2019

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

Brief description of study

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia

Detailed Study Description

This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

No statistical hypothesis tests will be performed.

Clinical Study Identifier: NCT02970929

Contact Investigators or Research Sites near you

Start Over

Raymond Manning, MD

CNRI-Los Angeles, LLC
Pico Rivera, CA United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.